Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice.

Volume: 10, Issue: 4, Pages: 402 - 409
Published: Jan 5, 2016
Abstract
Background and aims: Vedolizumab inhibits leucocyte vascular adhesion and migration into the gastrointestinal tract through α4β7 integrin blockade. This agent became available in mid-2014 for the treatment of moderate to severe Crohn’s disease (CD) and UC (UC). The aim of this study was to assess the patterns of use, effectiveness and safety of vedolizumab in an inflammatory bowel disease (IBD) clinical practice. Methods: Patients beginning...
Paper Fields
Paper Details
Title
Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice.
Published Date
Jan 5, 2016
Volume
10
Issue
4
Pages
402 - 409
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.